NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Lagerbericht

Marktkapitalisierung: US$128.5m

NGM Biopharmaceuticals Management

Management Kriterienprüfungen 2/4

NGM Biopharmaceuticals' CEO ist David Woodhouse, ernannt in Sep 2018, hat eine Amtszeit von 5.58 Jahren. Die jährliche Gesamtvergütung beträgt $5.93M, bestehend aus 10.3% Gehalt und 89.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.14% der Aktien des Unternehmens, im Wert von $179.29K. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.3 Jahre bzw. 5.6 Jahre.

Wichtige Informationen

David Woodhouse

Geschäftsführender

US$5.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts10.3%
Amtszeit als Geschäftsführer5.6yrs
Eigentum des Geschäftsführers0.1%
Durchschnittliche Amtszeit des Managements1.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5.6yrs

Jüngste Management Updates

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09
Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17
NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Mar 02
We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year

Jan 26
Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year

NGM Bio gives update on 2021 plans and data timeline

Jan 12

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von David Woodhouse im Vergleich zu den Einnahmen von NGM Biopharmaceuticals verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Dec 31 2023n/an/a

-US$142m

Sep 30 2023n/an/a

-US$151m

Jun 30 2023n/an/a

-US$170m

Mar 31 2023n/an/a

-US$178m

Dec 31 2022US$6mUS$610k

-US$163m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$135m

Mar 31 2022n/an/a

-US$125m

Dec 31 2021US$10mUS$580k

-US$120m

Sep 30 2021n/an/a

-US$121m

Jun 30 2021n/an/a

-US$122m

Mar 31 2021n/an/a

-US$111m

Dec 31 2020US$5mUS$525k

-US$102m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$72m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$2mUS$490k

-US$43m

Sep 30 2019n/an/a

-US$13m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$5m

Dec 31 2018US$4mUS$413k

-US$493k

Vergütung im Vergleich zum Markt: DavidDie Gesamtvergütung ($USD5.93M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD659.68K).

Entschädigung vs. Einkommen: DavidDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

David Woodhouse (52 yo)

5.6yrs

Amtszeit

US$5,933,500

Vergütung

Dr. David J. Woodhouse, Ph D., has been an Independent Director of Surrozen, Inc. since September 2020. Dr. Woodhouse joined the Surrozen, Inc. in September 2020.Dr. Woodhouse served as Acting Chief Finan...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
William Rieflin
Executive Chairman of the Board of Directors13.5yrsUS$1.10m3.32%
$ 4.3m
David Woodhouse
CEO & Director5.6yrsUS$5.93m0.14%
$ 179.3k
Valerie Pierce
Senior VP4.5yrsUS$2.10m0.022%
$ 28.7k
Hsiao Lieu
Chief Medical Officer & Executive VP5.1yrsUS$2.73m0.017%
$ 22.3k
Jean Frederic Viret
Chief Financial Officer1.3yrskeine Datenkeine Daten
Irene Perlich
VP, Corporate Controller & Principal Accounting Officerless than a yearkeine Daten0.011%
$ 13.8k
Daniel Kaplan
Chief Scientific Officer1.3yrskeine Datenkeine Daten
Mahi Saraf
Director of People & Cultureless than a yearkeine Datenkeine Daten
Diana Bockus
Head of Business Development1.8yrskeine Datenkeine Daten
Arthur Hsu
Senior Director & Head of Biology1.3yrskeine Datenkeine Daten
Kara Calhoun
Senior Vice President of CMC & Process Developmentless than a yearkeine Datenkeine Daten

1.3yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrenes Management: NGMDas Führungsteam des Unternehmens gilt nicht als erfahren (1.3 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
William Rieflin
Executive Chairman of the Board of Directors13.5yrsUS$1.10m3.32%
$ 4.3m
David Woodhouse
CEO & Director5.6yrsUS$5.93m0.14%
$ 179.3k
Grant Heidrich
Special Advisorno datakeine Datenkeine Daten
Arthur Levinson
Special Advisorno datakeine Datenkeine Daten
David Goeddel
Lead Independent Director5.6yrsUS$270.23k19.87%
$ 25.5m
Michael Brown
Chairman of the Scientific Advisory Boardno datakeine Datenkeine Daten
Joseph Goldstein
Member of the Scientific Advisory Boardno datakeine Datenkeine Daten
Roger Perlmutter
Independent Director2.8yrsUS$250.00k0%
$ 0
Shelly Guyer
Independent Director4.3yrsUS$273.09k0%
$ 0
Robert Schreiber
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Suzanne Hooper
Independent Director5.7yrsUS$265.00k0.0084%
$ 10.8k
Michael Fischbach
Member of Scientific Advisory Boardno datakeine Datenkeine Daten

5.6yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: NGMDie Vorstandsmitglieder gelten als erfahren (5.6 Jahre durchschnittliche Amtszeit).